Mycobacterial metabolism

Mycobacterial metabolism encompasses the complex network of biochemical reactions that sustain species of the genus Mycobacterium, particularly the human pathogen Mycobacterium tuberculosis. This metabolic framework is distinguished by its unique cell wall architecture, rich in long-chain fatty acids called mycolic acids, and a highly adaptable energy metabolism that allows the bacteria to persist in low-oxygen or nutrient-deprived host environments (Ehrt et al., 2018, Genes & Development). Unlike many other bacteria, mycobacteria preferentially utilize host-derived lipids and cholesterol as primary carbon sources during infection (Parish, 2020, Microbiology). From a therapeutic perspective, mycobacterial metabolism serves as a rich source of drug targets. Antibiotics such as isoniazid and ethambutol disrupt the synthesis of the protective cell wall, while newer agents like bedaquiline target the respiratory chain to deplete cellular ATP (Cook et al., 2014, Frontiers in Cellular and Infection Microbiology). Because of the metabolic plasticity of these organisms, including their ability to enter a dormant state, effective treatment often requires prolonged, multi-drug regimens to ensure complete clearance and prevent the emergence of resistance (Gygli et al., 2017, PubMed/Antimicrobial Resistance).

Other names

Mycobacterium tuberculosis metabolismMetabolic pathways of MycobacteriaMtb metabolismMycobacterial metabolic network

Drugs targeting mycobacterial metabolism typically function by inhibiting critical enzymes within specific pathways. For instance, Isoniazid inhibits Enoyl-ACP reductase (InhA), essential for mycolic acid synthesis (Parish, 2020, Microbiology). Bedaquiline inhibits the mycobacterial ATP synthase, disrupting energy production (Cook et al., 2014, Frontiers in Cellular and Infection Microbiology). Ethambutol targets arabinosyltransferases involved in cell wall assembly (Ehrt et al., 2018, Genes & Development).